Real Time Assays for Quantifying Cytotoxicity with Single Cell Resolution

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Hsiao, Sonny C ^a   Liu, Hong ^b   Holstlaw, Taylor A ^a   Liu, Cheng ^b   Francis, Catherine Y ^a   Francis, Matthew B ^c,d  

^a Research and Development Adheren Inc   (United States)

^b EUREKA THERAPEUTICS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ANTIBODY LABELING; ANTIBODY SPECIFICITY; ARTICLE; CELL ADHESION; CELL ASSAY; CELL DEATH; CELL IMMORTALIZATION; CELL VIABILITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DNA HYBRIDIZATION; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SINGLE CELL ANALYSIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL CULTURE; CYTOLOGY; MONONUCLEAR CELL; PHYSIOLOGY; TUMOR CELL LINE;

PROPIDIUM IODIDE;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; CELLS, CULTURED; HUMANS; LEUKOCYTES, MONONUCLEAR; PROPIDIUM;

EID: 84879465285     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066739     Document Type: Article

References (29)

1. Wang SY, Weiner G, (2008) Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Expert Opin Biol Ther 8: 759-768.
2. Dalle S, Thieblemont C, Thomas L, Dumontet C, (2008) Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem 8: 523-532.
3. Brunner KT, Mauel J, Cerottini JC, Chapuis B, (1968) Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14: 181-196.
4. Korzeniewski C, Callewaert DM, (1983) An enzyme-release assay for natural cytotoxicity. J Immunol Methods 64: 313-320.
5. Wu L, Adams M, Carter T, Chen R, Muller G, et al. (2008) Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 14: 4650-4657.
6. Johann S, Blümel G, Lipp M, Förster R, (1995) A versatile flow cytometry-based assay for the determination of short- and long-term natural killer cell activity. J Immunol Methods 185: 209-216.
7. Khattak SF, Spatara M, Roberts L, Roberts SC, (2006) Application of colorimetric assays to assess viability, growth and metabolism of hydrogel-encapsulated cells. Biotechnol Lett 2: 1361-1370.
8. Gerlier D, Thomasset NJ, (1986) Use of MTT colorimetric assay to measure cell activation. Immunol Methods 94: 57-63.
9. Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, et al. (2012) Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood 119: 3767-3778.
10. Hsiao SC, Shum BJ, Onoe H, Douglas ES, Gartner ZJ, et al. (2009) Direct cell surface modification with DNA for the capture of primary cells and the investigation of myotube Formation on defined patterns. Langmuir 25: 6985-6991.
11. Chandra RA, Douglas ES, Mathies RA, Bertozzi CR, Francis MB, (2006) Programmable cell adhesion encoded by DNA hybridization. Angew Chem Int Ed 45: 896-901.
12. Douglas ES, Hsiao SC, Onoe H, Bertozzi CR, Francis MB, et al. (2009) DNA-barcode directed capture and electrochemical metabolic analysis of single mammalian cells on a microelectrode array. Lab on a chip 9: 2010-2015.
13. Onoe H, Hsiao SC, Douglas ES, Gartner ZJ, Bertozzi CR, et al. (2012) Cellular microfabrication: observing intercellular interactions using lithographically-defined DNA capture sequences. Langmuir 28: 8120-8126.
14. Hsiao SC, Crow AK, Lam WA, Bertozzi CR, Fletcher DA, et al. (2008) DNA-coated AFM cantilevers for the investigation of cell adhesion and the patterning of live cells. Angew Chem Int Ed 47: 8473-8477.
15. Anderson DR, Grillo-López A, Varns C, Chambers KS, Hanna N, (1997) Targeted anti-cancer therapy using Rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 25: 705-708.
16. Kosits C, Callaghan M, (2000) Rituximab: a new monoclonal antibody therapy for non-Hodgkin's lymphoma. Oncol Nurs Forum 27: 51-59.
17. Plosker GL, Figgitt DP, (2003) Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63: 803-843.
18. Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, et al. (2002) Anti-CD20 antibody (IDEC-C2B8, Rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 87: 33-43.
19. Lv M, Lin Z, Qiao C, Gen S, Lang X, et al. (2010) Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity. Cancer Lett 294: 66-73.
20. Wu L, Wang C, Zhang D, Zhang X, Qian W, et al. (2010) Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma. Cancer Lett 292: 208-214.
21. Bornstein GG, Quéva C, Tabrizi M, van Abbema A, Chavez C, et al. (2010) Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs 28: 561-574.
22. Smith MR, (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22: 7359-7368.
23. Harjunpää A, Junnikkala S, Meri S, (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 51: 634-641.
24. Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, et al. (2003) Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo Rituximab resistance. J Clin Oncol 21: 1466-1471.
25. Amoroso A, Hafsi S, Militello L, Russo AE, Soua Z, et al. (2011) Understanding Rituximab function and resistance: implications for tailored therapy. Front Biosci 16: 770-782.
26. Gancz D, Fishelson Z, (2009) Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development. Mol Immunol 46: 2794-2800.
27. Vugmeyster Y, Howell K, Bakshl A, Flores C, Canova-Davis E, (2003) Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. Cytometry A 52: 101-109.
28. Brouzes E, Medkova M, Savenelli N, Marran D, Twardowski M, et al. (2009) Droplet microfluidic technology for single-cell high-throughput screening. Proc Natl Acad Sci U S A. 106: 14195-14200.
29. Liadi I, Roszik J, Romain G, Cooper LJ, Varadarajan N, (2013) Quantitative high-throughput single-cell cytotoxicity assay for T cells. J Vis Exp. 2: e50058.